Lawmakers in at least 10 states will consider taxes on makers of opioids in the upcoming legislative session depending on the results of the November election; the numbers may be low, but overdose deaths in Alaska involving fentanyl more than quadrupled in 2017; a new company created by health systems to address drug shortages and high-cost generics is taking shape with a name and a chief executive officer.
Minnesota almost succeeded in taxing makers of opioids, and the state’s lawmakers plan to try again in January 2019. The state isn’t alone—lawmakers in at least 10 other states will consider opioid taxes, reported Kaiser Health News. New York launched its own opioid tax on July 1. The proceeds of the tax would help pay for addiction treatment and prevention, but whether or not states follow through on implementing these taxes will likely depend on if Democrats retake governorships and legislatures in the November election.
The numbers may be low, but overdose deaths in Alaska involving fentanyl more than quadrupled in 2017. The Associated Press reported that 37 people died of fentanyl overdoses last year compared with just 8 the year before. With a small population, Alaska has had one of the highest per-capita death rates for prescription opioid overdoses. As the state’s illegal drug problem has worsened, so has associated crimes, like theft and violence.
In January 2018, a group of health systems announced they would band together to form a nonprofit generic drug company the address shortages and high-cost generics. Now, that company is taking shape. Civica Rx will be independent but include a board of governing members that include health systems like Intermountain Healthcare and the Mayo Clinic, and the company’s CEO will be Martin Van Trieste, a former Amgen executive, according to NPR. The company plans to market 14 common generic drugs, although the names of those drugs haven’t been released yet. They were chosen because they have been in short supply and their prices have recently risen.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Homelessness Compounds Hospital Stay Challenges: Study Reveals Prolonged Discharge Struggles
March 28th 2024In this investigation, outcomes of interest were morbidity rate and length of hospital stay or a traumatic injury among a homeless population, and whether age and/or injury severity had an influence on that relationship—with implications for improving the discharge process for these patients.
Read More
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More